Jeffrey Hatfield
Director/Board Member at VIR BIOTECHNOLOGY, INC.
Net worth: 160 115 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Toselli | M | 66 | 7 years | |
| Charles Sigal | M | 72 | 21 years | |
| Marianne de Backer | M | 55 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
| Jay Parrish | M | 49 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | 8 years |
| Rosana Kapeller-Libermann | M | 60 |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | 5 years |
| James Sapirstein | M | 63 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 14 years |
| Richard Heyman | M | 66 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 7 years |
| Heather M. Hamel | F | - | 7 years | |
| Joanne Duncan | F | - |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 13 years |
| Kira Nelson | F | 55 |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | - |
| Aleksandra Rizo | M | 49 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
| George Scangos | M | 76 | 7 years | |
| Robert Nelsen | M | 60 | 8 years | |
| Tim Coughlin | M | 57 | 7 years | |
| Svetlana Lucas | M | 52 | 5 years | |
| Jane Gross | M | 67 | 5 years | |
| Lynne Krummen | M | - | 6 years | |
| Vahe Bedian | M | - | 4 years | |
| Ashlee Dunston | F | - | 4 years | |
| Kimberly McCutcheon Jablonski | F | - | 21 years | |
| Sung Lee | M | 53 | 1 years | |
| Janet Napolitano | F | 65 | 4 years | |
| Peter Harwin | M | 38 | 4 years | |
| Sona Saira Ramasastry | F | 48 | 5 years | |
| Sandra Leung | F | 63 | 32 years | |
| Kyle Kuvalanka | M | 56 |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | 1 years |
| Tomas Kiselak | M | 38 | 4 years | |
| Arlene Morris | F | 72 | 6 years | |
| Robert Perez | M | 59 | 7 years | |
| Robert More | M | 56 | 8 years | |
| Phillip Sharp | M | 79 | 7 years | |
| Vicki Sato | M | 75 | 8 years | |
| Rick Winningham | M | 64 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 15 years |
| Kristina Burow | F | 50 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | 5 years |
| Benjamin Cravatt | M | 54 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 10 years |
| Angela Sheen | M | - | 4 years | |
| Stephen M. Kaufhold | M | - | 8 years | |
| Jeff Calcagno | M | - | 1 years | |
| Carole A. Sable | M | 62 | 8 years | |
| Steven Kafka | M | 54 |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | 3 years |
| Ambrose Bailey | M | 60 | 8 years | |
| Sasha Ellis | F | - | 1 years | |
| Kira M. Schwartz | F | - | 8 years | |
| Kenneth Joseph Keller | M | 61 | 10 years | |
| Richard van Duyne | M | - | 10 years | |
| Glenn Gormley | M | - | 10 years | |
| Aine M. Hanly | M | 54 | 3 years | |
| Richard Lepke | M | - | - | |
| Carly Scaduto | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 years | |
| Christopher McNulty | M | 47 | 5 years | |
| Lamberto Andreotti | M | 73 | 19 years | |
| William Marshall | M | 60 | 3 years | |
| Jonathan Violin | M | 49 | 3 years | |
| Howard Horn | M | 47 | 6 years | |
| Peter R. Dolan | M | 68 | 18 years | |
| John Mendlein | M | 64 | 9 years | |
| Lee Rauch | F | - | 1 years | |
| Jason A. Leverone | M | 50 | 4 years | |
| Charles A. Heimbold | M | - | 20 years | |
| Bruce Booth | M | 49 | 12 years | |
| Charles Rowland | M | 65 | 11 years | |
| Mark D. Perrin | M | 67 | 3 years | |
| Faheem Hasnain | M | 65 | 7 years | |
| Christopher Bowden | M | 63 | 7 years | |
| Adam Levy | M | 46 | 3 years | |
| Isai Peimer | M | 46 | 3 years | |
| Frederic Bittenbender | M | - |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | - |
| Fouad Namouni | M | 55 | 21 years | |
| Scott Applebaum | M | 57 | - | |
| Rosemary Crane | F | 64 | 20 years | |
| Jason Haddock | M | 54 | 14 years | |
| Melanie Morel-Ferris | F | 44 | 1 years | |
| Dipchand Nishar | M | 55 | 5 years | |
| Allan P. Marchington | M | 56 | 7 years | |
| Tamara Joseph | F | 61 | - | |
| Standish M. Fleming | M | 76 | 13 years | |
| David Parkinson | M | 73 | 1 years | |
| John E. Elicker | M | 64 | 20 years | |
| Laurie Glimcher | M | 72 | 20 years | |
| Gerald Steiner | M | 63 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 11 years |
| Kenneth DiPietro | M | 65 | 6 years | |
| Bryan Roberts | M | 57 | 15 years | |
| Anthony Hooper | M | 69 | 15 years | |
| Mark Foletta | M | 63 | - | |
| Alan Fuhrman | M | 67 | 4 years | |
| Barry J. Wolfenson | M | 57 | 23 years | |
| Charles Newhall | M | 79 | 14 years | |
| Brian Daniels | M | 65 | 14 years | |
| Lewis B. Campbell | M | 77 | 18 years | |
| Leif Valdemar Johansson | M | 73 | 13 years | |
| Kyle A. Lefkoff | M | 64 | - | |
| Robert Gunderson | M | 72 | 14 years | |
| David Bonita | M | 48 | 2 years | |
| Joseph Squicciarino | M | 67 | 22 years | |
| Steven B. Ratoff | M | 81 | 16 years | |
| Gerald Bruce | M | 68 | 8 years | |
| Lara Meisner | F | 52 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeffrey Hatfield
- Personal Network